Comparative bioavailability of two oral formulations of bromazepam in healthy volunteers

The aim of this study was to assess the pharmacokinetic profile of two bromazepam (CAS 1812-30-2) formulations in 24 healthy volunteers. An open, randomised clinical trial designed as two-period crossover with 14-day washout between doses was employed. Plasma samples for assessments of their bromazepam concentration by HPLC-UV were obtained over 96 h after administration. No adverse effect was reported for any of the formulations administered. The following pharmacokinetics parameters were calculated: AUC((0-96h)), AUC(lnf), C-max, T-max, K-e and T-1/2. The 90 % confidence Intervals (CI) for the mean test/reference Individual ratios were 81-109 for AUC and 84-116 for C-max. Since the 90 % CI for both, AUC and C-max ratios were within the 80-125 % interval proposed by the Food and Drug Administration, it is concluded that the new bromazepam slow-release formulation Is therapeutic equivalent to the conventional formulation for both, the extent and the rate of absorption after single dose administration in healthy volunteers.